piperaquine has been researched along with Infection Reactivation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buff, AM; Chebore, W; Desai, M; Kariuki, S; Otieno, K; Owidhi, M; Samuels, AM; Westercamp, N | 1 |
| Chepngetich, J; Gachie, B; Gathirwa, J; Kiboi, D; Kimani, F; Magoma, G; Muriithi, B; Mwitari, P; Onchieku, N; Thiong'o, K | 1 |
2 other study(ies) available for piperaquine and Infection Reactivation
| Article | Year |
|---|---|
Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria among Children in Western Kenya, 2016 to 2017.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Ethanolamines; Fluorenes; Folic Acid Antagonists; Humans; Infant; Kenya; Malaria; Malaria, Falciparum; Piperazines; Plasmodium falciparum; Quinolines; Reinfection | 2022 |
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Humans; Kenya; Lumefantrine; Malaria; Malaria, Falciparum; Mutation; Plasmodium falciparum; Prevalence; Quinolines; Reinfection | 2023 |